Mortality/major ischemic events at 90 days were no lower than with a restrictive strategy—but cardiac complications differed.

The device may help boost early detection of HFrEF for people living in low-resource settings where echo is scarce.

With such a large reduction, coupled with general skepticism around PUFAs, experts would like to see the trial replicated.

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.